Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indevus Submits Data To FDA With New Dosing Regimen For Hypogonadism Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Change in dose, additional data should not impact June 27 PDUFA date for Nebido, company says.
Advertisement

Related Content

Third Time’s A Charm? Endo’s Injectable Testosterone Finally Ready For Advisory Cmte.
FDA Safety Concerns About Indevus’ Nebido Could Add 24 Months To Approval Timeline
FDA Safety Concerns About Indevus’ Nebido Could Add 24 Months To Approval Timeline
Indevus Submits Nebido For Hypogonadism
Indevus Submits Nebido For Hypogonadism
Indevus Plans End-Of-Summer NDA For Nebido Following Positive Phase III Results
Indevus To Market Nebido In The U.S. Upon Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS066762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel